Science

Robert Brodsky

Feb 27, 2025, 13:40

Robert Brodsky: Haploidentical Bone Marrow Transplantation for Sickle Cell Disease

Robert Brodsky, President of American Society of Hematology and Chief of Hematology at Johns Hopkins, shared an article by Adetola A. Kassim, et al. on X:

“Out in NEJM Evidence today.

KEY TAKEAWAYS:

Of 42 people with severe SCD who had the procedure , 95% were alive at 2 yrs, and 88% are considered cured.
Most people with SCD are eligible, which costs a fraction of the price of gene editing/therapy.

Haploidentical Bone Marrow Transplantation for Sickle Cell Disease.

Authors: Adetola A. Kassim, et al.

Robert Brodsky: Haploidentical Bone Marrow Transplantation for Sickle Cell Disease

Adetola A. Kassim American Society of Hematology ASH Bone Marrow Transplantation cancer fight against cancer Global fight against cancer Johns Hopkins NEJM OncoDaily Oncology Robert Brodsky sickle cell disease

FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

New Paper Alert Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective Experience

Highlights from TTLC2025

KIMMTRAK (Tebentafusp) uses in Cancer: Dosages, Indications, Expectations and more

Senator Edward Markey in Response to OncoDaily About Pediatric Cancer Funding